If you have been following the history on the MMR patents, then you know that most of their patents have been related to personal health records but the company also has biotech interests including  thousands of patient tumor samples, etc.  CD20 monoclonal antibodies are used in the treatment of B-cell Non-Hodgkin disease.  The original announcement was here back in 2008 with the merger. 

Favrille Biotech and MyMedicalRecords.com, Inc. Announce Merger Agreement

The company has been pursuing patent violations relative to personal health records and below is an example and a link with one EHR company who has signed an agreement to license MMR Health IT patents.  BD

4Medica Electronic Medical Records Company Signs Agreement With MMRGlobal (MyMedicalRecord) To License Health IT Patents

LOS ANGELES, CA -- (Marketwired) -- 04/22/13 -- MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that the Australian Patent Office has issued a Notice of Allowance (NOA) for the Company's anti-CD20 monoclonal antibody assets, #2007338607, under the title, "Antibodies and Methods for Making and Using Them." The patent application was originally filed on September 14, 2007. The Australian NOA is significant to the Company in that it reinforces the value of the U.S. antibody patent that was announced by the Company on April 15th, 2013 and the similar antibody patent issued in Mexico in August 2012. These patents for the Company's anti-CD20 monoclonal antibodies have particular utility in fighting cancers and are considered important assets of the Company based on benefits and commercial value demonstrated by Rituxan®, an anti-CD20 monoclonal antibody with reported sales of USD $7.285 billion in 2012, which is due to go off patent in 2015. Additional patent applications for the Company's antibodies are pending in a number of other countries including Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea. In addition to its biotech patents.

The Company acquired its biotechnology portfolio as a result of a reverse merger with Favrille, Inc., a biopharmaceutical company, in January 2009.  Favrille invested more than $100 million in research and development on its FavId™/Specifid™ vaccine trials and use of customized tumor cells to treat lymphoma patients and other technologies.  MMR's biotech assets include an extensive portfolio including its anti-CD20 monoclonal antibodies, data from vaccine trials, thousands of patient tumor samples and other intellectual property of which the Company has been advised by experts may have inestimable value.



Post a Comment